GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » INVO Fertility Inc (NAS:NAYA) » Definitions » Debt-to-EBITDA

NAYA (INVO Fertility) Debt-to-EBITDA : -1.22 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is INVO Fertility Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

INVO Fertility's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1.95 Mil. INVO Fertility's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $3.39 Mil. INVO Fertility's annualized EBITDA for the quarter that ended in Sep. 2024 was $-4.39 Mil. INVO Fertility's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was -1.22.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for INVO Fertility's Debt-to-EBITDA or its related term are showing as below:

NAYA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.96   Med: -0.24   Max: -0.05
Current: -0.96

During the past 13 years, the highest Debt-to-EBITDA Ratio of INVO Fertility was -0.05. The lowest was -0.96. And the median was -0.24.

NAYA's Debt-to-EBITDA is ranked worse than
100% of 441 companies
in the Medical Devices & Instruments industry
Industry Median: 1.47 vs NAYA: -0.96

INVO Fertility Debt-to-EBITDA Historical Data

The historical data trend for INVO Fertility's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INVO Fertility Debt-to-EBITDA Chart

INVO Fertility Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.26 -0.14 -0.41 -0.21 -0.92

INVO Fertility Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.52 -0.96 -1.35 -0.82 -1.22

Competitive Comparison of INVO Fertility's Debt-to-EBITDA

For the Medical Devices subindustry, INVO Fertility's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


INVO Fertility's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, INVO Fertility's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where INVO Fertility's Debt-to-EBITDA falls into.


;
;

INVO Fertility Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

INVO Fertility's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.691 + 4.61) / -6.88
=-0.92

INVO Fertility's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.948 + 3.387) / -4.388
=-1.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


INVO Fertility  (NAS:NAYA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


INVO Fertility Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of INVO Fertility's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


INVO Fertility Business Description

Traded in Other Exchanges
N/A
Address
5582 Broadcast Court, Sarasota, FL, USA, 34240
INVO Fertility Inc is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care to patients in need. It is offering the intravaginal culture (IVC) procedure enabled by INVOcell medical device (INVOcell). The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body.
Executives
Trent D Davis director 811 SW NAITO PARKWAY, SUITE 200, PORTLAND OR 97204
Matthew K Szot director 802 NORTH DOUTY STREET, HANFORD CA 93230
Steve Shum director 9025 SW HILLMAN COURT, SUITE 3126, WILSONVILLE OR 97070
Andrea Goren officer: Chief Financial Officer 110 EAST 59TH STREET, SUITE 1901, NEW YORK NY 10022
Barbara Ryan director 22 CAVRAY ROAD, NORWALK CT 06855
Michael Jos. Campbell director 61 SOUTH HILLS DRIVE, BEDFORD NH 03110
Rebecca Messina director 5582 BROADCAST COURT, SARASOTA FL 34240
Jeffrey Segal director INVO BIOSCIENCE, INC., 5582 BROADCAST COURT, SARASOTA FL 34240
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Kevin Doody director, officer: Medical Director 1109 SOMERSET BLVD, COLLEYVILLE TX 76034
Debra Robbins Hoopes officer: Acting CFO and PFO 1 MORTON DR., SUITE 200, CHARLOTTESVILLE VA 22903
Claude Ranoux 10 percent owner 8 CHESTNUT STREET, WINCHESTER MA 01890
Kathleen T Karloff director, officer: CEO/Chairman 109 BEACON STREET UNIT 5, BOSTON MA 02116
Bowdring Robert Joseph Jr officer: Chief Financial Officer 92 GOULD STREET, WAKEFIELD MA 01880